Population structure and spatial distribution of Mycobacterium tuberculosis in Ethiopia.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read More Add to Saved list
  • Additional Information
    • Source:
      Publisher: Nature Publishing Group Country of Publication: England NLM ID: 101563288 Publication Model: Electronic Cited Medium: Internet ISSN: 2045-2322 (Electronic) Linking ISSN: 20452322 NLM ISO Abbreviation: Sci Rep Subsets: MEDLINE
    • Publication Information:
      Original Publication: London : Nature Publishing Group, copyright 2011-
    • Subject Terms:
      Mycobacterium tuberculosis*/genetics ; Mycobacterium tuberculosis*/drug effects ; Mycobacterium tuberculosis*/isolation & purification; Ethiopia/epidemiology ; Humans ; Female ; Male ; Adult ; Middle Aged ; Adolescent ; Young Adult ; Tuberculosis, Multidrug-Resistant/epidemiology ; Tuberculosis, Multidrug-Resistant/microbiology ; Tuberculosis/epidemiology ; Tuberculosis/microbiology ; Bacterial Typing Techniques
    • Abstract:
      Ethiopia is one of the countries with a high tuberculosis (TB) burden, yet little is known about the spatial distribution of Mycobacterium tuberculosis (Mtb) lineages. This study identifies the spoligotyping of 1735 archived Mtb isolates from the National Drug Resistance Survey, collected between November 2011 and June 2013, to investigate Mtb population structure and spatial distribution. Spoligotype International Types (SITs) and lineages were retrieved from online databases. The distribution of lineages was evaluated using Fisher's exact test and logistic regression models. The Global Moran's Index and Getis-Ord Gi statistic were utilized to identify hotspot areas. Our results showed that spoligotypes could be interpreted and led to 4 lineages and 283 spoligotype patterns in 91% of the isolates, including 4% of those with multidrug/rifampicin resistance (MDR/RR) TB. The identified Mtb lineages were lineage 1 (1.8%), lineage 3 (25.9%), lineage 4 (70.6%) and lineage 7 (1.6%). The proportion of lineages 3 and 4 varied by regions, with lineage 3 being significantly greater than lineage 4 in reports from Gambella (AOR = 4.37, P < 0.001) and Tigray (AOR = 3.44, P = 0.001) and lineage 4 being significantly higher in Southern Nations Nationalities and Peoples Region (AOR = 1.97, P = 0.026) than lineage 3. Hotspots for lineage 1 were located in eastern Ethiopia, while a lineage 7 hotspot was identified in northern and western Ethiopia. The five prevalent spoligotypes, which were SIT149, SIT53, SIT25, SIT37 and SIT26 account for 42.8% of all isolates under investigation, while SIT149, SIT53 and SIT21 account for 52-57.8% of drug-resistant TB cases. TB and drug resistant TB are mainly caused by lineages 3 and 4, and significant proportions of the prevalent spoligotypes also influence drug-resistant TB and the total TB burden. Regional variations in lineages may result from both local and cross-border spread.
      (© 2024. The Author(s).)
    • References:
      BMJ Glob Health. 2017 Jul 28;2(2):e000318. (PMID: 29081999)
      Nat Commun. 2021 Oct 20;12(1):6099. (PMID: 34671035)
      Microbiologyopen. 2019 Jun;8(6):e00744. (PMID: 30318822)
      J Clin Microbiol. 1997 Apr;35(4):907-14. (PMID: 9157152)
      Philos Trans R Soc Lond B Biol Sci. 2012 Mar 19;367(1590):850-9. (PMID: 22312052)
      BMC Microbiol. 2021 May 28;21(1):157. (PMID: 34044775)
      Nat Genet. 2016 Dec;48(12):1535-1543. (PMID: 27798628)
      Proc Natl Acad Sci U S A. 2002 Feb 5;99(3):1538-43. (PMID: 11818527)
      Database (Oxford). 2020 Dec 15;2020:. (PMID: 33320180)
      Genes (Basel). 2022 May 31;13(6):. (PMID: 35741753)
      Sci Rep. 2019 Jun 26;9(1):9305. (PMID: 31243306)
      Front Med (Lausanne). 2022 Oct 14;9:960590. (PMID: 36313999)
      PLoS One. 2019 Jul 12;14(7):e0219706. (PMID: 31299060)
      BMC Med. 2018 Oct 30;16(1):196. (PMID: 30373589)
      Sci Rep. 2020 Mar 20;10(1):5142. (PMID: 32198367)
      Front Microbiol. 2020 Sep 22;11:550760. (PMID: 33072011)
      BMC Microbiol. 2006 Mar 06;6:23. (PMID: 16519816)
      Genes (Basel). 2022 Mar 08;13(3):. (PMID: 35328028)
      Int J Infect Dis. 2021 Jan;102:489-496. (PMID: 33059094)
      Emerg Infect Dis. 2013 Mar;19(3):460-3. (PMID: 23622814)
      Emerg Infect Dis. 2020 Mar;26(3):427-436. (PMID: 32091355)
      BMC Microbiol. 2021 Apr 21;21(1):123. (PMID: 33879047)
      J Clin Microbiol. 2015 Apr;53(4):1301-9. (PMID: 25673798)
      J Prev Med Hyg. 2020 Apr 30;61(1 Suppl 1):E16-E18. (PMID: 32529100)
      PLoS One. 2018 Sep 17;13(9):e0198054. (PMID: 30222743)
      Microb Genom. 2021 Feb;7(2):. (PMID: 33555243)
      PLoS One. 2016 Aug 12;11(8):e0160434. (PMID: 27518286)
      Proc Natl Acad Sci U S A. 2006 Feb 21;103(8):2869-73. (PMID: 16477032)
      BMC Infect Dis. 2014 Dec 19;14:703. (PMID: 25523472)
      F1000Res. 2021 Feb 1;10:60. (PMID: 33732436)
    • Grant Information:
      D43 TW009127 United States TW FIC NIH HHS
    • Publication Date:
      Date Created: 20240507 Date Completed: 20240507 Latest Revision: 20240510
    • Publication Date:
      20240510
    • Accession Number:
      PMC11076284
    • Accession Number:
      10.1038/s41598-024-59435-3
    • Accession Number:
      38714745